keytruda melanoma - Search News

Moderna's cancer vaccine hits key goal in melanoma trial

Moderna, Merck Melanoma Vaccine May Help Reduce Recurrence, Spread

Moderna and Merck announced August 19 that a phase 3 trial of their experimental personalized mRNA cancer therapy, intismeran, in combination with Keytruda (pembrolizumab), met two key endpoints in pe...

· 1d · on MSN

Can Moderna's melanoma vaccine cure cancer? Here's what researchers say

· 2d · on MSN

Moderna and Merck say melanoma vaccine succeeded in large trial

Channel NewsAsia Singapore · 1d

Moderna, Merck say mRNA treatment cuts risk of melanoma recurrence, spread

US pharma giants Moderna and Merck have scored a breakthrough in a vaccine that could allow people with a type of skin cancer to live longer.

· 14h

Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer

· 1d

Moderna’s 177% surge burns shorts

· 1d

Moderna breakthrough brings back memories of pandemic mania

its mRNA-based melanoma vaccine, jointly developed with Merck, doesn’t just offer a potentially massive market itself, but may also lead to breakthroughs for other cancers, including lung, bladder and...

India Today · 1d

Moderna & Merck Cancer Vaccine Clears Phase 3 Trial | How Personalised mRNA Tech Fights Melanoma

· 1d

From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran;

New Melanoma Vaccine in Development Might Prevent Recurrence, Spread of Deadly Skin Cancer

Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according to the pharmaceutical companies. In a press release, they said the vaccine showed evidence of reducing the risk of cancer spreading and extending time without melanoma returning in a late-stage trial.